Clinical Trial Update: INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating INCB039110 in combination with dabrafenib and trametinib in patients with BRAF-mutant melanoma and other solid tumors has terminated; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• INCB039110 (Itacitinib)
• Trametinib (trametinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2023-09-22